peter
ball
mb
chb
chest
term
chronic
bronchiti
appear
introduc
unit
kingdom
earli
centuri
describ
chronic
bronchial
mucos
inflamm
british
popul
continu
suffer
one
highest
mortal
rate
chronic
bronchiti
europ
mani
adult
men
thought
affect
howev
problem
worldwid
distribut
million
american
per
year
suffer
episod
ofbronch
excess
canadian
symptom
chronic
obstruct
pulmonari
diseas
suggest
adult
middl
year
unit
state
affect
precis
relationship
infect
exacerb
progress
diseas
individu
remain
uncertain
huge
sum
expend
year
antibiot
treatment
exacerb
indic
widespread
belief
efficaci
treatment
among
medic
profess
howev
recent
studi
lower
respiratori
tract
infect
acut
exacerb
chronic
bronchiti
aecb
suggest
major
patient
respond
satisfactorili
tradit
antibiot
broad
spectrum
penicillin
other
may
factor
distinguish
group
ofless
respons
patient
recent
investig
overview
examin
epidemiolog
diseas
current
chemotherapeut
modal
method
assess
treatment
respons
suggest
avenu
discriminatori
evalu
new
agent
epidemiolog
classic
studi
adult
bronchit
patient
london
indic
onset
mainli
third
decad
onward
preval
rose
steadili
fifth
sixth
decad
predominantli
smoke
men
lower
social
class
pattern
diseas
remain
unchang
survey
patient
unit
kingdom
year
later
medic
histori
clinic
featur
patient
confirm
classic
definit
chronic
unit
kingdom
govern
statist
indic
respiratori
ill
account
cash
sick
benefit
total
relat
chronic
obstruct
airway
diseas
comparison
asthma
although
onset
phase
ill
take
mani
year
patient
signific
respiratori
obstruct
develop
prognosi
poor
mortal
cohort
nonatop
smoker
rose
compar
nonsmok
asthmat
subject
annual
death
rate
chronic
bronchiti
variou
countri
taken
world
health
organ
statist
shown
figur
unit
kingdom
death
diseas
exacerb
among
adult
men
rank
third
myocardi
infarct
lung
cancer
statist
annual
predomin
lower
social
class
male
death
rate
rang
social
class
ldo
ooo
respect
class
epidemiolog
survey
exampl
england
wale
suggest
recurr
respiratori
tract
infect
childhood
consequ
upon
poor
social
condit
may
predispos
develop
chronic
bronchiti
later
life
factor
may
greater
influenc
geograph
distribut
diseas
cigarett
smoke
howev
numer
studi
shown
posit
correl
mortal
rate
chronic
bronchiti
smoke
perhap
convincinr
describ
relationship
among
british
doctor
industri
pollut
major
precipit
massiv
increas
mortal
accompani
london
lo
angel
smog
reid
fairbairn
previous
defin
relationship
fog
work
absente
due
varieti
microorgan
shown
associ
exacerb
chronic
bronchiti
tabl
howev
preemin
pathogen
haenwphilu
influen
ae
recogn
sinc
caus
bacteriolog
defin
exacerb
initi
attempt
confirm
invas
natur
pathogen
detect
serolog
respons
exacerb
origin
provid
conflict
data
later
evid
indic
posit
associ
demonstr
previous
neg
result
methodolog
origin
frequenc
isol
h
injluenza
increas
respiratori
obstruct
worsen
role
initi
perpetu
viciou
circl
hwothesi
bronchial
damag
appear
beyond
doubt
role
haemophilu
parainjluenza
less
certain
smith
colleagu
identifi
organ
frequent
found
correl
symptom
decreas
pulmonari
function
anoth
studi
patient
found
organ
almost
sputum
cultur
propmtion
major
respiratori
pathogen
isol
patient
recent
clinic
trial
indic
tabl
moraxella
catarrhali
streptococcu
pneumonia
account
approxim
third
isol
aecb
although
persist
p
resent
respiratori
secret
establish
fl
uhe
l
death
rate
per
popul
adult
age
chronic
bronchit
patient
h
influen
ae
pneumococci
isol
significantli
frequent
infect
exacerb
evid
suggest
may
persist
low
number
sputum
appar
effect
therapi
aecb
phenoic
isol
respons
subsequ
relaps
virus
mycoplasma
probabl
respons
third
exacerb
chlamydia
import
precipit
acut
bronchiti
play
minor
role
causat
aecb
majmiti
patient
aecb
present
primari
care
physician
receiv
antibiot
therapi
unit
kingdom
account
substanti
proport
million
antibiot
issu
per
year
intercontinent
medic
statist
mdi
dec
mat
howev
patient
lower
respiratori
tract
infect
treat
domiciliari
basi
return
within
matter
week
persist
syrnptom
thu
necessari
question
whether
antibiot
therapi
per
se
effect
aecb
whether
certain
newer
antibiot
improv
vitro
activ
pharmacokinet
like
prove
effect
tradit
agent
broad
spectrum
penicillin
perhap
even
import
assess
evid
efficaci
rapid
effect
therapi
acut
exacerb
prevent
inexor
declin
respiratori
function
characteris
diseas
anthonisen
colleagu
found
acut
reduct
fev
associ
aecb
improv
rapidli
antibiot
therapi
placebo
howev
comprehens
literatur
review
found
one
studi
indic
recurr
infect
exacerb
longterm
detriment
effect
pulmonari
function
chronic
bronchit
depict
tabl
efficaci
otherwis
antimicrobi
chemotherapi
remain
mani
year
controversi
issu
variou
placebocontrol
studi
rel
small
number
patient
provid
conflict
evid
benefit
antibioticsl
late
anthonisen
cowork
publish
larg
scale
placebocontrol
studi
patient
defin
exacerb
indic
signific
benefit
antibiot
therapi
patient
alloc
antibiot
therapi
receiv
either
amoxycillin
cotrimoxazol
doxycyclin
although
result
overal
indic
signific
differ
favor
antibiot
treatment
optim
benefit
observ
patient
exacerb
character
increas
dyspnea
sputum
product
sputum
purul
often
term
winnipeg
criteria
subsequ
italian
group
h
studi
similarli
size
popul
show
highli
signific
differ
favor
coamoxyclav
augmentin
compar
placebo
patient
standard
diseas
sever
group
base
assess
empir
score
system
incorpor
winnipeg
criteria
togeth
addit
factor
includ
presenc
degre
pyrexia
sever
cough
presenc
coexist
cardiopulmonari
diseas
result
earlier
studi
shown
tabl
vari
result
histor
contemporari
studi
chemotherapi
aecb
may
number
explan
least
nonhomogen
patient
popul
studi
improv
chemotherapi
year
question
increas
preval
bacteri
resist
also
major
influenc
choic
tradit
agent
novel
antibiot
either
insuscept
capabl
bypass
common
resist
mechan
howev
insist
mani
registr
author
new
drug
must
compar
tradit
agent
amoxycillin
standard
evalu
isol
sensit
investig
compar
agent
often
result
failur
prove
clear
ad
ratio
vantag
frequent
shown
pneumonia
trial
intent
treat
analys
may
far
indic
subsequ
clinic
role
new
agent
problem
follow
use
criteria
propos
winnipeg
group
although
criteria
defin
exacerb
defin
etiolog
thu
noninfect
viral
exacerb
may
compar
bacteri
exacerb
inevit
confus
result
sensit
respiratori
tract
pathogen
tradit
antibiot
may
longer
assum
nationwid
studi
unit
state
canada
indic
betalactamasemedi
amoxycillin
resist
among
nonencapsul
strain
h
influenza
risen
approxim
figur
mirror
rate
poland
unit
associ
increas
nonbetalactamasemedi
betalactam
resist
impli
resist
coamoxyclav
resist
sulphamethoxazol
rimethoprim
cefaclor
choic
among
appropri
agent
manag
aecb
clearli
constrain
local
resist
rate
broad
recommend
use
standard
betalactam
cotrimoxazol
tetracyclin
erythromycin
longer
justifi
profound
differ
penetr
differ
antibiot
class
tissu
secr
tabl
cefaclor
tion
respiratori
tract
implic
factor
treatment
acut
exacerb
chronic
bronchiti
merit
initi
consider
although
precis
relationship
clearli
establish
sputum
bronchial
mucos
concentr
antibiot
consid
potenti
predict
outcom
therapi
lower
respiratori
infect
gener
betalactam
attain
simultan
serum
concentr
sputum
bronchial
secret
wherea
erythromycin
chloramphenicol
tetracyclin
often
achiev
ratio
quinolon
produc
concentr
bronchial
secret
serum
azithromycin
highz
concentr
sputum
bronchial
secret
level
ofbetalactam
bronchial
mucosa
higher
perhap
serum
concentr
quinolon
rang
azithromycin
may
greater
ratio
concentr
obtain
respiratori
tissu
fluid
serum
shown
tabl
ratio
attain
sputum
bronchial
secret
bronchial
mucos
concentr
relat
h
irifluenza
pneumococcu
depict
figur
high
ratio
predict
greater
clinic
efficaci
relationship
refer
follow
paragraph
deal
individu
class
antibiot
mani
origin
trial
antibiot
therapi
aecb
util
tetracyclin
two
earli
studi
prophylaxi
exacerb
indic
reduct
day
lost
work
patient
receiv
oxytetracyclin
howev
number
exacerb
winter
month
reduc
studi
pursu
earli
treatment
studi
suggest
treat
patient
might
recov
sooner
deterior
less
often
control
subject
pine
perform
mani
studi
tetracyclin
conclud
basi
experi
other
tetracyclin
therapi
effect
placebo
milder
infect
deriv
effect
tetracyclin
sever
infect
requir
larg
dose
prophylact
use
larg
ineffect
contrast
nicotra
et
ap
found
differ
tetracyclin
placebo
end
treatment
moder
ill
patient
maesen
colleagu
repeat
studi
doxycyclin
attempt
reassess
place
compound
contemporari
therapi
clinic
result
excel
good
patient
h
influenza
major
pathogen
aecb
present
difficulti
erad
nevertheless
author
consid
doxycyclin
remain
use
oral
antibiot
manag
aecb
especi
use
infect
caus
catarrhali
tetracyclin
use
minor
aecb
resist
dictat
use
sever
ill
patient
minim
ventilatori
reserv
although
earli
placebocontrol
studi
fail
show
conclus
advantag
activ
therapi
aecb
ampicillin
successor
amoxycillin
becom
wide
use
agent
manag
aecb
drug
choic
patient
mildtomoder
exacerb
countri
counti
resist
among
h
irifluenza
pneumococci
remain
low
level
may
ingold
consid
amoxycillin
superior
ampicillin
although
basi
followup
studi
chodosh
would
undoubtedli
disagre
variou
regimen
evalu
includ
comparison
standard
day
amoxycillin
therapi
cours
patient
receiv
g
twice
daili
high
dose
amoxycillin
well
toler
signific
differ
two
group
mean
number
exacerb
year
follow
therapi
similar
although
mean
time
first
exacerb
longer
week
high
dose
therapi
compar
week
receiv
standard
treatment
cours
impress
array
data
attest
efficaci
agent
mild
moder
aecb
caus
sensit
organ
accumul
drug
develop
studi
use
compar
patient
categor
suffer
lower
respiratori
tract
infect
major
suffer
acut
bronchiti
aecb
differ
demonstr
ciprofloxacin
ofloxacin
azithromycin
clarithromycin
oral
broadspectrum
penicillin
studi
patient
sever
episod
aecb
fulfil
winnipeg
criteria
occas
shown
advantag
compar
ampicillin
amoxycillin
exampl
azithromycin
ciprofloxacin
despit
rel
poor
activ
suboptim
respiratori
pharmacokinet
cephalexin
cefaclor
use
extens
manag
aecb
therefor
recent
commonli
use
standard
compar
clinic
trial
new
agent
sever
infect
cefaclor
gave
poor
result
ciprofloxacin
prove
significantli
superior
newer
cephalosporin
eg
cefixim
cefprozil
may
advantag
comparison
newer
oral
cephalosporin
amoxycillin
rare
shown
signific
advantag
provid
organ
fulli
sensit
agent
although
studi
patient
lower
respiratori
infect
shown
coamoxiclav
equival
standard
compar
number
demonstr
superior
amoxycillin
parenter
cefuroxim
follow
oral
cephalexin
cefaclor
josamycin
comparison
ciprofloxacin
show
signific
differ
overview
data
clinic
trial
demonstr
coamoxiclav
valuabl
agent
infect
caus
betalactamas
produc
h
injluenza
catarrhali
howev
controversi
still
surround
degre
penetr
amoxycillin
clavulan
acid
bronchial
mucosa
rang
simultan
serum
level
estim
one
group
investig
other
earli
agent
ampicillin
amoxycillin
enjoy
popular
cotrimoxazol
administr
schedul
enhanc
complianc
origin
clinic
trial
result
suggest
combin
might
effect
ycillin
variou
tetracyclin
howev
followup
studi
suggest
benefit
maintain
convalesc
comparison
oral
cephalosporin
gener
show
signific
differ
lacey
cowork
demonstr
equal
trimethoprim
alon
cotrimoxazol
among
patient
varieti
oflow
respiratori
tract
infect
howev
recognit
toxici
cotrimoxazol
especi
elderli
patient
increas
avail
safer
agent
potenti
enhanc
activ
result
dramat
declin
use
compound
europ
late
infrequ
wellrecogn
marrow
toxic
chloramphenicol
would
remain
extrem
use
agent
chronic
bronchiti
perhap
worthi
reapprais
patient
sever
exacerb
diseas
highli
activ
h
injluenza
princip
pathogen
among
isol
resist
rate
low
rang
europ
although
significantli
higher
spain
concentr
bronchial
secret
exceed
simultan
serum
level
anecdot
report
benefit
sever
ill
patient
minim
respiratori
reserv
commonplac
definit
clinic
studi
lack
late
presenc
widespread
resist
betalactam
may
reassess
place
chloramphenicol
sever
exacerb
overdu
erythromycin
poor
activ
h
injluenza
mic
mgil
consid
one
drug
choic
aecb
azithromycin
clarithromycin
improv
pharmacokinet
tabl
antibacteri
activ
azithromycin
much
enhanc
potenc
h
injluenza
mic
mg
l
compar
favor
amoxycillin
coamoxiclav
patient
winnipeg
type
two
signific
advantag
azithromycin
appar
first
daili
administr
abbrevi
cours
aid
complianc
second
reduc
frequenc
relaps
extend
followup
day
show
differ
respons
rate
advers
reaction
agent
may
consid
patient
moder
sever
exacerb
standard
agent
becom
compromis
multipl
previou
use
emerg
resist
despit
gloomi
prognost
question
activ
fluoroquinolon
pneurrwnia
suggest
clinic
respons
rate
might
exceed
agent
ciprofloxacin
ofloxacin
proven
remark
effect
aecb
potenc
h
influenza
catarrhali
superior
penetr
sputum
bronchial
mucosa
reflect
favor
comparison
betalactam
tradit
agent
review
efficaci
fluoroquinolon
aecb
indic
respons
rate
trial
ciprofloxacin
frequent
demonstr
superior
standard
agent
ampicillin
cefaclor
cephalexin
josamycin
term
bacteri
erad
notabl
h
injluenza
prior
abrupt
withdraw
temafloxacin
enhanc
activ
pneumococcu
appear
promis
futur
sparfloxacin
also
similarli
improv
activ
prove
equival
coamoxiclav
evalu
intent
treat
analys
doubleblind
multicent
studi
adult
exacerb
conform
winnipeg
type
criteria
increas
preval
resist
standard
antibiot
among
respiratori
pathogen
may
soon
elev
fluoroquinolon
posit
primari
choic
manag
moderatetosever
exacerb
outcom
support
develop
new
compound
bay
cp
even
greater
gramposit
activ
new
approach
assess
sinc
landmark
studi
anthonisen
suggest
criteria
empir
ground
thought
predict
sever
exacerb
mani
studi
incorpor
assess
despit
trial
succeed
demonstr
superior
novel
agent
offer
signific
improv
antibacteri
activ
respiratori
tissuefluid
penetr
standard
antibiot
thu
ciprofloxacin
ofloxacin
clarithromycin
azithromycin
prove
superior
agent
amoxycillin
cefaclor
studi
base
assess
end
therapi
confirm
equival
case
may
relat
assess
criteria
use
thu
studi
fluoroquinolon
davi
group
clinic
respons
pathogen
erad
insist
upon
reappear
pathogen
followup
studi
week
therapi
may
interpret
overal
failur
howev
increasingli
recogn
h
influenza
pneumococci
may
persist
bronchial
secret
despit
appar
satisfactori
clinic
respons
call
question
method
assess
clinic
comparison
made
week
complet
treatment
may
prove
discriminatori
exampl
pine
colleagu
found
differ
amoxycillin
cotrimoxazol
end
therapi
third
receiv
cotrimoxazol
remain
free
relaps
followup
compar
receiv
amoxycillin
differ
statist
signific
chodosh
analyz
longterm
followup
data
seri
trial
aecb
shown
mean
time
end
therapi
one
exacerb
onset
next
may
allow
reliabl
assess
compar
efficaci
thu
time
relaps
ampicillin
therapi
day
taken
index
valu
ratio
period
applic
agent
calcul
use
approach
poor
perform
oral
cephalosporin
emphas
ratio
cephalexin
cefaclor
indic
much
earlier
relaps
treatment
compound
contrast
efficaci
quinolon
demonstr
method
ciprofloxacin
day
relaps
temafloxacin
day
offer
ratio
equal
excess
uniti
compar
ampicillin
similar
approach
taken
bennet
measur
time
next
exacerb
also
number
exacerb
year
follow
therapi
altern
respons
assess
fix
interv
exampl
petri
cowork
found
relaps
rate
month
azithromycin
therapyofhospit
patient
conform
winnipeg
type
exacerb
criteria
significantli
lower
vs
patient
treat
amoxycillin
clearli
advantag
quinolon
new
macrolid
azalid
augment
rel
lack
resist
among
respiratori
pathogen
exampl
recent
studi
note
isol
aecb
ampicillinsensit
howev
although
studi
compli
accept
definit
chronic
bronchiti
exacerb
interpret
result
clinic
trial
complic
lack
standard
sever
ill
popul
studi
empir
base
system
winnipeg
criteria
italian
composit
score
b
may
defin
acut
exacerb
studi
undertaken
correl
observ
outcom
thu
sever
perform
observ
studi
patient
acut
exacerb
record
histor
clinic
paramet
present
followup
relat
outcom
util
stepwis
logist
regress
techniqu
result
show
may
accur
defin
exacerb
none
winnipeg
criteria
increas
dyspnea
sputum
product
sputum
purul
either
singli
combin
predict
outcom
two
factor
found
posit
predict
return
famili
practition
similar
symptom
within
week
initi
present
frequent
exacerb
within
previou
year
signific
comorbid
unrel
cardiopulmonari
diseas
latter
factor
conform
similar
observ
relat
outcom
bacteri
pneumonia
trial
compar
new
quinolon
macrolid
azalid
antibiot
class
tradit
compound
futur
perform
patient
conform
winnipeg
criteria
involv
assess
end
therapi
extend
followup
real
differ
might
appear
favor
new
agent
could
translat
improv
patient
care
